MESO · Mesoblast
AI read · Good for MESO
The AI's read
More sales and lower cash use can give Mesoblast more room to fund its work. More RYONCIL patient starts suggest demand is growing. The heart-failure filing has not been submitted, and the low-back-pain trial has no result in this report. Those unfinished steps temper the news, but the reported sales and cash-use gains point to a favorable update.